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ABSTRACT 
Objective: Current models of the oral glucose tolerance test (OGTT) do not contain the substantive contributions of the incretin hormones, glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1), to glucose-stimulated insulin secretion. In this paper, the modified oral 
minimal model and the incretin effects were introduced. Mathematical model of glucose levels and the changes in incretin was used to simulate the 
responses to 75 grams oral glucose loads under normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM).  
Methods: In the standard OGTT, plasma glucose concentrations are measured at time 0, 10, 20, 30, 60, 90, 120, 150, and 180 min, following an oral 
glucose load of 75 grams. The OGTT is a simple clinical test currently used to aid diagnosis of NGT, IGT, and T2DM subjects. In this work, the 
modified oral minimal model and the incretin effects were used to study investigated in the published data of the OGTT. 
Results: The accuracy of the model and its applicability to understanding fundamental mechanisms was further assessed using the calculated 
coefficient of determination, R2, from parameter estimates and the majority of the parameters were matched to known experimental data. The 
averaged R2value between measured and calculated plasma concentrations is 0.920, which indicates agreement with experiment data. 
Conclusion: The loss of incretin effects is secondary to the development of diabetes. Thus, patients with diabetes secondary to destruction of 
insular tissues in patients with chronic pancreatitis exhibit an almost complete loss of incretin effects, whereas patients with a similar degree of 
chronic pancreatitis, as judged from pancreatic function tests but normal glucose tolerance (NGT), have a normal uncertain effect. 
Keywords: Diabetes Mellitus, GIP, GLP-1, Incretin, Mathematical model, OGTT. 
 
INTRODUCTION 
Many different models have been developed that describe the 
glycemic and hormonal responses to an intravenous glucose load, as 
well as determining the impact of insulin sensitivity and glucose 
effectiveness on these responses. However, the intravenous glucose 
tolerance test (IVGTT) used to obtain the parameters in this model is 
invasive and requires considerable cooperation on the part of the 
patient. 
In the others test, the oral glucose tolerance test (OGTT) is a much 
simpler procedure to perform, with both decreased invasiveness and 
the reduced burden on the patient. OGTT’s is thus routinely 
performed in clinical laboratories to diagnose IGT, gestational 
diabetes and T2DM subjects. Only a few mathematical models of the 
OGTT have been developed to date, and these models do not 
explicitly take into account the relatively recent findings of the 
significant contributions of intestinal hormones to oral glucose-
stimulated insulin secretion.  
Two-major incretin have been identified, these being glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 
(GLP-1). Both of these hormones are released in response to glucose 
delivery from the stomach into the duodenum, and levels remain 
elevated until the ingested glucose is absorbed from the 
gastrointestinal (GI) tract. Studies have demonstrated that GIP and 
GLP-1 contribute approximately equally to the incretin effects, 
stimulating both first and second phase insulin secretion. Since these 
hormones are believed to be the major contributors to the incretin 
effects, the aggregate effects of these incretinare represented by 
means of a single variable within which each is assumed to be 
similarly weighted [1]. 
The OGTT mimics the physiological conditions of the glucose system 
more closely than the IVGTT. However, analysis of the OGTT data of 
a mathematical model is affected by the complication that the time 
course of the delivery of plasma of exogenous glucose and even the 
total amount of glucose delivered is unknown. In fact, the rate of 
appearance, Rα, of exogenous glucose in plasma is influenced by 
several factors: the rate of gastric emptying of ingested glucose, the 
extent of absorption during the intestinal transit, glucose amount 
used by the gut as energy substrate, and hepatic uptake. Moreover, a 
gut-derived hormones, secreted in response to glucose delivery to 
the small intestine, markedly increase the insulin secretion with 
respect to that observed after an intravenous glucose infusion that 
produces the same elevation of plasma glucose (incretin effects) [1]. 
The present model is thus a single compartment representation that 
is intended primarily to illustrate the importance of the incretin. The 
model thus developed describes the physiological responses, within 
the limits of a one compartment model, not only to oral glucose, but 
also to change in insulin sensitivity. Insulin sensitivity (SI) is the 
ability of insulin to enhance glucose utilization and inhibit glucose 
production, is an important parameter to assess the efficiency of the 
glucose regulatory system. This SI index, useful not only for diagnosis 
but also for assessing the efficacy of a given therapy, is usually 
measured using methods involving an intravenous administration of 
glucose, such as the IVGTT test interpreted with the minimal model 
[1-4]. However, these techniques realize experimentally a non-
physiological since the rapid glucose perturbations of an IVGTT 
reflect the condition of daily living. Therefore, it is highly desirable 
to have a method able to quantify SI index in a normal life 
physiological, e. g., during a meal. Unfortunately, the estimation of SI 
index after an oral glucose perturbation is not an easy task, the 
major obstacle being that the rate of appearance of glucose 
absorption is unknown. More reliability, probably the reference 
method fores timating SI index during a meal, is a procedure; the 
rate of appearance of absorbed glucose is reconstructed as 
accurately as possible with a non-tracer method [2]. Once the rate of 
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appearance of absorbed glucose is known, to estimate SI index one 
has to explain the meal plasma glucose measurements with a model 
describing insulin action on glucose production and disposal. In fact, 
when glucose and insulin change smoothly as during an oral test, the 
single-compartment description of glucose kinetics has proven to be 
sufficiently accurate [2]. 
The aim of this paper, we have proposed a modified oral minimal 
model based on oral minimal models for glucose kinetics by Dalla et 
al. [2]. We present the modified oral minimal model with new 
plasma insulin kinetics. We also presented in this model with plasma 
insulin compartment for the change of the incretin. 
MATERIALS AND METHODS 
All measured experimental data from reference [5], the study 
investigated 150 Caucasian participants (Northern European) 
enrolled at Copenhagen University Hospital, Denmark, and 120 
Japanese participants (Japanese) enrolled at Tokyo University 
Hospital, Japan. For all participants, an OGTT was performed with an 
oral bolus corresponding to 75 grams dissolved glucose. Plasma 
samples for measurement of glucose concentrations were collected 
at times 0, 10, 20, 30, 60, 90, 120, 150, and 180 min relative to the 
time of glucose uptake.  
In this research, mathematical models, developed with the aim of 
describing the kinetics of the insulin system during an OGTT and 
estimating parameters of clinical interest, are presented. Attention is 
focused on some of the more recent contributions. Methods and 
models used for the analysis of non-tracer data have not been 
considered in the present work. The OGTT minimal model [2] 
extends to the oral test the basic model proposed for the IVGTT, with 
the modification that glucose administration does no longer appear 
as a bolus dose in the initial condition of the equation for glucose 
kinetics, but as an input function that specifies the rate of 
appearance of oral glucose in plasma. The model describes the 
kinetics of the plasma glucose concentration G(t) (basal glucose 
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Where I(t) is the plasma insulin concentration (basal insulin value, 
Ib). Insulin concentration data, assumed to be error-free, are used to 
construct an input function of the system. Rα is the rate of 
appearance of oral glucose in plasma. Parameters p1, p2, and p3 are 
parameters with the same meaning as in the IVGTT minimal model. 
The definition of SI index is the ability of insulin to enhance glucose 
utilization and inhibit glucose production, it is proposed to compute 
the SI from time t = 0 to t = ∞, so that:  
SIOGTT = p3p2 V = SIV. (dl. kg-1. min-1. μU-1. mL).(3) 
The SI index is computed by taking into account the OGTT measurements 
throughout the test. Computations make use of a trivial linear 
relationship where Rα forces the glucose excursion above its basal value, 
and of the assumption that glucose and insulin concentrations achieve 
the pre-test basal values at the end of the test. The SI estimates, derived 
from a long (300 min) and a short (120 min) oral test were compared 
with those obtained from an intravenous test. As this last requirement is 
not usually satisfied in the clinical setting, parametric descriptions of the 
rate of appearance were evaluated. The approach chosen was that of 
representing the Rα by a piecewise linear function with a given number 
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With t0= 0 and α0= 0 (Rα(0) = 0). The αi values are to be estimated 
from the glucose concentration data. In this way, for each subject, 
the SI index, the parameter p2, and the piecewise-linear 
reconstruction of the Rα were estimated. The Rα was found to have a 
similar profile in healthy subjects and diabetic patients, and 73-76% 
of the oral load was recovered in the circulation in the 3-5hstudy 
period. The rate of gastric emptying and small intestine transit time 
appear to be the main factors in determining glucose Rα [2]. Data of 
gastric retention of glucose (dose fraction retained vs. time) were 
reported by a power exponential function and the rate of glucose 
delivery into the duodenum was computed. 
In the present model, the modified oral minimal model with plasma 
insulin compartment under the assumption that if the plasma 
glucose compartments up the take above the basal glucose levels, 
the rate of insulin entering the plasma glucose compartment is 
presented by equation (5). Insulin is cleared from the plasma insulin 
compartment at a rate proportional to the amount of insulin in the 
plasma insulin compartment. In this equation, plasma insulin levels 
also reflect the effects of the incretin (k2) on the beta cell. The 
clearance of insulin from the circulation was set in accordance with 
the reported metabolic clearance rate in humans [1]. This clearance 
value governs the entire disposition of insulin from plasma, about 
one-half of which occurs in its passage through the liver. We also 
presented plasma insulin compartment for the plasma glucose 
compartment drops below the basal glucose levels, so the plasma 
glucose compartment is zero (see equation (6)). Finally, the 
differential equation governing insulin kinetics is thus:  
dIt
dt
= γGt − Gbt− k1It − Ib + k2Inc, I0 = Ib, if G(t)>Gb, (5) 
dIt
dt
= −kIt − Ib,I0 = Ib, if G(t)<Gb,(6) 
Where, k1 is the insulin clearance fraction. Gb is the basal glucose 
level. γ is a measure of the secondary pancreatic response to glucose. 
Inc is plasma incretin concentration (GIP+GLP-1). 
Glucose G(t) and insulin I(t) data are submitted to the modified oral 
minimal model program, which estimates the model parameters 
from the real data. This program is based on the nonlinear least-
squares estimation method. I(t) = Ib is submitted to the modified oral 
minimal model program, which predicts a glucose time course, 
G(t),which fits data G(t) as closely as possible in the least-squares 
sense. In the course of the fitting, the model yields X (t), an estimate 
of X(t), as well as estimates of parameters p1, p2, and p3. The 
coefficient of determination, R2is calculated from parameter 
estimates. This latter parameter is represented as SI and SG are equal 
to p3/p2 and p1 as defined in equations (1) and (2), where
ŷ is the 
prediction of the non-linear least-squares fitting.  
The residuals between the best-fit curve and the data, ii
yy ˆ−
[6]: 
R2 = 1 − ∑ yiyi2ni1∑ yiyi2ni1 .(7) 
RESULTS  
The averaged coefficient of determination, R2, between measured 
and calculated plasma concentrations is 0.920, which indicates 
agreement with experimental data. We considered sets of parameter 
values consistent with adaptation to data from actual OGTT 
experiments [5].  
Simulations are performed by using MATLAB ordinary 
differential equation solver ode45 and non-linear least-squares 
method. Moreover, in observing that indeed the oral glucose 
belongs to the initial condition of the ordinary differential 
equation model (1) – (6) 
 
Table 1: Parameters of OGTT using modified oral minimal 
model and the incretin effects 
 NGT IGT T2MD 








SG[min-1] 0.037±0.002 0.03±0.002 0.011±0.001 
Gb[mg/dl] 90±4.5 105±5.3 143±7.2 
Ib[μU/ml] 8±0.4 11±0.55 13±0.65 
Inc[ng/l] 200±10 150±7.5 80±4 
mean±SD 
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Fig. 1: Profile of normal glucose tolerance (NGT) in [5] produced 
by equations (1)-(7) with parameters: k = 0.3, γ = 0.004, Gb = 90 
[mg/dl], Ib = 8 [μU/ml], p2 = 0.0115 [min-1], SI= 11.16 ×10-4 
[ml/kg. min. μU-1 ml], SG = 0.037 [min-1], I0 = 10 [μU/ml], G0 = 75 
[mg/dl], Inc = 200 [ng/l] and R2 = 0.920 
 
 
Fig. 2: Profile of impaired glucose tolerance (IGT) in [5] 
produced by equations (1)-(7) with parameters: k = 0.85, γ = 
0.018, Gb = 105 [mg/dl], Ib = 11 [μU/ml], p2 = 0.002 [min-1], SI = 
8.1×10-4 [ml/kg. min. μU-1 ml], SG = 0.03 [min-1], I0 = 10 [ μU/ml], 
G0 = 75 [mg/dl],Inc = 150 [ng/l] and R2 = 0.920 
 
 
Fig. 3: Profile of diabetes mellitus (DM) in [3, 4] produced by 
equations (1)-(7) with parameters: k = 0.13, γ = 0.00081, Gb = 
143 [mg/dl], Ib = 13 [μU/ml], p2 = 0.07 [min-1], SI = 1.87×10-4 
[ml/kg. min. μU-1 ml], SG = 0.011 [min-1], I0 = 13[ μU/ml], G0 = 75 
[mg/dl], Inc = 80 [ng/l] and R2 = 0.920 
The concentration of plasma glucose during the OGTT is shown in 
fig. 1, fig. 2, and fig. 3. Of note is that by the end of the OGTT at 200 
min, glucose levels had virtually returned to their respective basal 
levels. Of course, this does not prove that all oral glucose had been 
absorbed or that the metabolism of oral glucose was complete. 
Fig. 1, fig. 2 and fig. 3 shows that the glucose curves are very 
different. The fig. also indicates that the profiles of glucose levels of 
the subjects categorized as of subjects with NGT, IGT or T2DM are 
very different. Fig. 2 shows that the compensation of increased 
insulin secretion in IGT is not obvious. Accordingly, the IGT subjects, 
who can only be identified by accessing the 1hplasma glucose, are 
definitely different from subjects with NGT. Attention should be paid 
to such subjects, before they fall into the pre-diabetes and diabetes 
criteria of the World Health Organization (WHO) and the American 
Diabetes Association (ADA). 
DISCUSSION 
In this study, we introduce an approach that exploits the modified 
oral minimal model, but adds a parsimonious parametric 
representation of splanchnic glucose absorption that allows the 
measurement of insulin sensitivity in each individual. Obviously, 
such a calculation is simpler to perform than the nonlinear 
estimation procedure required for this method. 
We have examined this approach to derive estimates of SI index from 
oral glucose tolerance data in NGT, IGT, or T2DMsubjects. In table 1, 
insulin sensitivity (SI) and incretin hormone (Inc) of the IGT and 
T2DM subjects were decreased, whereas glucose effectiveness (SG) 
of the IGT and T2DM subjects also was decreased. This information 
is provided that the SI, SG and Inc measured by the modified oral 
minimal model can diagnose pre-diabetes and type 2 diabetic 
subjects. Comparing the SI index obtained with this approach with 
the OGTT by correlation analysis revealed a strong and highly 
significant correlation between the SI indexes measured in the 
experimental data.  
This result suggests that this method is measuring similar 
physiological phenomena, most likely the sum effects of insulin to 
enhance glucose uptake by peripheral tissues (mostly muscle) and 
concomitantly suppress liver glucose output.  
The comparison between insulin sensitivity indexes obtained by an 
oral minimal model (OMM) by Dalla et al. [5] ((11.68±2) × 10-4 
ml/kg. min. μU-1 ml)and this present model ((11.16±0.56) × 10-4 
ml/kg. min. μU-1 ml) indicates an excellent agreement in average 
between the estimates of insulin sensitivity, the correlation between 
the two indexes is satisfactory. 
Therefore, our results indicate that the modified oral minimal model 
applied to the analysis of OGTT data is potentially useful to measure 
SI index when use of the FSIGT is not feasible for economic or 
practical reasons. The present study in NGT, IGT, or T2DM subjects 
is the first attempt and an obvious prerequisite. Further work is 
needed to define the domain of validity of this method throughout 
the whole range of SI index and assess its applicability to patients 
with pre-diabetes and diabetes mellitus. If validated in disease 
states, the new test may be preferable to the OGTT in larger studies 
because of its simplicity. 
Several lines of evidence support that the loss of an incretin effect is 
secondary to the development of pre-diabetes and diabetes mellitus. 
Thus, patients with diabetes secondary to destruction of insular 
tissues in patients with chronic pancreatitis exhibit an almost 
complete loss of incretin effects, whereas patients with a similar 
degree of chronic pancreatitis, as judged from pancreatic imaging 
and function tests but normal glucose tolerance (NGT), have a 
normal uncertain effect. 
CONCLUSION 
The model presented a unique approach by which the glucose 
responses to oral glucose can be simulated using 6 equations. The 
incorporation of the incretin effects into this model allows for a 
more accurate representation of the known physiology of the 
glucose regulatory system. 
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More importantly, the major difference between the current model 
and those proposed by others, is the explicit incorporation of an 
incretin term that allows for the stimulatory effects of the 
gastrointestinal hormones, GLP-1 and GIP, on glucose-stimulated 
insulin secretion. A simulation of an OGTT by preventing the oral 
glucose-induced rise in increments (fig. 1), demonstrated that, for an 
identical glucose load.  
Thus, the biological actions of the incretins to stimulate insulin 
secretion must be an essential component of any model that 
simulates the glucose regulatory responses to oral nutrients and are, 
for the first time, explicitly included here in a simple mathematical 
model. 
In conclusion, impaired secretion of the incretin hormones may not 
be a constant finding, but decreased secretion of the incretin after 
mixed meals is observed in this study. Given that the sensitivity of 
the pancreatic islets to the actions of the incretin hormones is 
decreased in type 2 diabetes (see table 1), it is evident that impaired 
secretion, when present, will aggravate the loss of incretin effect in 
these patients. 
ACKNOWLEDGMENT 
This study was funded by the Direktorat Jenderal Pendidikan Tinggi 
Kementerian Pendidikandan Kebudayaan Indonesia through 
research funding from the HibahPenelitian Batch I, Program 
Penelitian Unggulan Perguruan Tinggi (PUPT), Tahun Anggaran 
2015, Nomor: 603/IT3.11/PI/2015, Institut Pertanian Bogor (IPB), 
Indonesia. 
CONFLICT OF INTERESTS 
The authors report no conflicts of interest. 
REFERENCES 
1. Brubaker PL, Ohayon EL, D’Alessandro LM, Norwich KH. A 
mathematical model of the oral glucose tolerance test 
illustrating the effects of the incretins. Ann Biomed Eng 
2007;35:1286–300. 
2. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C. 
Minimal model estimation of glucose absorption and insulin 
sensitivity of oral test: validation with a tracer method. Am J 
Physiol Endocrinol Metab 2004;287:E637–43. 
3. Kartono A. Modified minimal model for effect of physical exercise 
on insulin sensitivity and glucose effectiveness in type 2 diabetes 
and healthy human. Theory Biosci 2013;132:195-206. 
4. Nurullaeli, Kartono A, Dahlan K. Mathematical model of the 
intravenous glucose tolerance test using modified minimal 
model. Far East J Mathematical Sci 2013;6:587-96. 
5. Moller JB. Model based analysis of ethnic differences in type 2 
diabetes, PhD Thesis, Informatics and mathematical modelling, 
Technical university of Denmark; 2011. 
6. Chapra SC, Canale RP. Numerical methods for engineers. 6th 
Ed. New York: McGraw-Hill Publisher; 2010. 
 
